Basel, 30th July 2004 Novartis Pharma AG announced today that the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending that the European Commission (EC) grant a Marketing Authorisation for Emselex
(darifenacin hydrobromide), 7.5mg and 15mg, for the treatment of overactive bladder (OAB) in all 25 European Union (EU) countries as well as Norway and Iceland. Upon receipt of the EC approval, Novartis will be able to market Emselex
throughout these countries.
"We are delighted by the CHMP's positive opinion for Emselex, to provide overactive bladder sufferers with a new safe and effective treatment option", said Jrg Reinhardt, Global Head of Development Novartis Pharma AG. "Due to its M3 selectivity, Emselex provides effective overactive bladder symptom relief while decreasing the potential risk of safety issues such as cognitive impairment or effects on cardiac function."
OAB affects almost one in six adults in Europe1. Symptoms of overactive bladder are urinary urgency (a sudden compelling desire to pass urine, which is difficult to defer) with or without urge incontinence (involuntary leakage accompanied by urgency), urinary frequency (voiding the bladder too often), and nocturia (waking at night one or more times to void the bladder).
The CHMP based its positive opinion on Emselex's comprehensive data package for OAB. The safety and efficacy of Emselex has been extensively studied in over 90 pre-clinical studies and clinical trials, involving more than 5,000 patients. Pivotal studies explored key endpoints including the reduction in the number of incontinence episodes per week, the reduction in the number of voluntary urination episodes (micturition) per day, the reduction in the episodes and severity of urgency and an increase in the average volume of urine passed per micturition.
The phase III clinical Page: 1 2 3 Related medicine news :1
. UIC professor receives international humanitarian award2
. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant3
. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award4
. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix5
. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program6
. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program7
. American Academy of Neurology program receives Grassroots Award8
. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers9
. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI10
. Pfizers antifungal medicine VFEND receives FDA approval11
. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder